GleamWall
中文EN

REPL Replimune Group, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1737953 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY12.6%
TTM EPS YoY19.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-115.8%
ROA-71.0%
ROIC (approx.)-209.7%
Asset turnover—

Leverage & solvency

Liabilities / assets45.2%
Debt / equity0.49x
Current ratio7.11x
Interest coverage-30.18x

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31
Income statement
Revenue——
R&D expense$221.18M$189.45M
SG&A expense$98.73M$72.18M
Operating income-$319.92M-$261.63M
Interest expense$6.80M$5.78M
Pretax income-$314.49M-$246.83M
Income tax-$551,000$468,000
Net income-$313.94M-$247.30M
EBITDA-$316.59M-$258.12M
EPS (basic)-3.38-3.07
EPS (diluted)-3.38-3.07
Weighted avg. shares (diluted)92.80M80.56M
Balance sheet
Cash & equivalents$209.02M$112.82M
Short-term investments$59.87M$372.69M
Inventory$0—
Current assets$279.12M$495.88M
PP&E, net$12.97M$13.74M
Total assets$332.39M$551.33M
Current liabilities$58.23M$62.36M
Long-term debt$83.31M$46.38M
Total debt$83.31M$46.38M
Total liabilities$166.23M$135.49M
Shareholders' equity$166.16M$415.84M
Net debt-$125.72M-$66.44M
Shares outstanding82.72M77.09M
Cash flow statement
Operating cash flow-$280.34M-$192.25M
Capital expenditure$4.22M$6.69M
Free cash flow-$284.57M-$198.94M
Investing cash flow$310.84M-$23.80M
Financing cash flow$66.29M$252.40M
Depreciation & amortization$3.33M$3.50M
Stock-based compensation$32.27M$35.04M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.